Clinical trial
Proof-of-concept Study to Assess Urinary PGE-MUM Concentration (PROSTAGLANDIN E-MAJOR URINARY METABOLITE) as a Potential Marker of Inflammation in Inflammatory Bowel Disease (IBD) - Comparison With Fecal Calprotectin Level (FC)
NCT05171452 is registered in ClinicalTrials.gov with Assistance Publique - Hôpitaux de Paris as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Proof-of-concept Study to Assess Urinary PGE-MUM Concentration (PROSTAGLANDIN E-MAJOR URINARY METABOLITE) as a Potential Marker of Inflammation in Inflammatory Bowel Disease (IBD) - Comparison With Fecal Calprotectin Level (FC)
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
- Phase
- Observational
- Overall status
- Completed
- Start date
- October 3, 2019
- Completion date
- October 19, 2020
- Enrollment
- 101 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.